Sun Mon Tue Wed Thu Fri Sat
1
2
CEDSS Seminar: “Disseminated cell hybrids as biomarkers for cancer detection, prognosis and treatment response” 11:00 am
CEDSS Seminar: “Disseminated cell hybrids as biomarkers for cancer detection, prognosis and treatment response” @ Zoom - See Description for Zoom Link
Mar 2 @ 11:00 am – 12:00 pm
CEDSS Seminar: "Disseminated cell hybrids as biomarkers for cancer detection, prognosis and treatment response" @ Zoom - See Description for Zoom Link
“Disseminated cell hybrids as biomarkers for cancer detection, prognosis and treatment response” Melissa Wong, Ph.D. Associate Professor and Vice Chair Department of Cell, Development and Cancer Biology Program Co-Lead, Knight Cancer Institute Oregon Health &[...]
3
4
5
6
7
8
9
Frontiers in Cancer Clinical Translation-“Molecular Imaging in Prostate Cancer: PSMA is Here, What (if Anything) Next?” 8:00 am
Frontiers in Cancer Clinical Translation-“Molecular Imaging in Prostate Cancer: PSMA is Here, What (if Anything) Next?” @ Zoom: https://stanford.zoom.us/j/8927817254?pwd=bytJQi9lK2xLL2JIM2JiRVFVeG5iZz09
Mar 9 @ 8:00 am – 9:00 am
Frontiers in Cancer Clinical Translation-"Molecular Imaging in Prostate Cancer: PSMA is Here, What (if Anything) Next?" @  Zoom: https://stanford.zoom.us/j/8927817254?pwd=bytJQi9lK2xLL2JIM2JiRVFVeG5iZz09
Presenter: Andrei Iagaru M.D. “Molecular Imaging in Prostate Cancer: PSMA is Here, What (if Anything) Next?” Professor of Radiology (Nuclear Medicine) Stanford University Medical Center
10
11
12
13
14
15
16
17
18
19
20
21
22
23
Frontiers in Cancer Clinical Translation-“Immune-Related Adverse Events (irAEs) from Immune Checkpoint Inhibitors: Where should we go from here?” 8:00 am
Frontiers in Cancer Clinical Translation-“Immune-Related Adverse Events (irAEs) from Immune Checkpoint Inhibitors: Where should we go from here?” @ Zoom: https://stanford.zoom.us/j/8927817254?pwd=bytJQi9lK2xLL2JIM2JiRVFVeG5iZz09
Mar 23 @ 8:00 am – 9:00 am
Frontiers in Cancer Clinical Translation-“Immune-Related Adverse Events (irAEs) from Immune Checkpoint Inhibitors: Where should we go from here?” @ Zoom:  https://stanford.zoom.us/j/8927817254?pwd=bytJQi9lK2xLL2JIM2JiRVFVeG5iZz09
Presenter: Tamiko Katsumoto M.D. “Immune-Related Adverse Events (irAEs) from Immune Checkpoint Inhibitors: Where should we go from here?” Clinical Assistant Professor, Department of Medicine Division of Immunology and Rheumatology  
Virtual PHIND Symposium 9:30 am
Virtual PHIND Symposium @ Virtual Livestream
Mar 23 @ 9:30 am – 4:05 pm
Virtual PHIND Symposium @ Virtual Livestream
The PHIND Center is part of the Department of Radiology and is the first center in the world to focus on precision health and integrated diagnostics. We bring together faculty from all across campus to[...]
24
25
MIPS Seminar: “Circulating Tumor DNA Biomarkers for Therapy Monitoring and Early Detection” 12:00 pm
MIPS Seminar: “Circulating Tumor DNA Biomarkers for Therapy Monitoring and Early Detection” @ Zoom - See Description for Zoom Link
Mar 25 @ 12:00 pm – 12:45 pm
MIPS Seminar: “Circulating Tumor DNA Biomarkers for Therapy Monitoring and Early Detection” @ Zoom - See Description for Zoom Link
“Circulating Tumor DNA Biomarkers for Therapy Monitoring and Early Detection”   Shan X. Wang, PhD Leland T. Edwards Professor in the School of Engineering Professor of Materials Science & Engineering, jointly of Electrical Engineering, and[...]
26
27
28
29
30
Frontiers in Cancer Clinical Translation-“Ocular toxocities of new generation targeted agents” 8:00 am
Frontiers in Cancer Clinical Translation-“Ocular toxocities of new generation targeted agents” @ Zoom: https://stanford.zoom.us/j/8927817254?pwd=bytJQi9lK2xLL2JIM2JiRVFVeG5iZz09
Mar 30 @ 8:00 am – 9:00 am
Frontiers in Cancer Clinical Translation-"Ocular toxocities of new generation targeted agents” @ Zoom:  https://stanford.zoom.us/j/8927817254?pwd=bytJQi9lK2xLL2JIM2JiRVFVeG5iZz09
Presenter: Prithvi Mruthyunjaya, M.D., MHS “Ocular toxocities of new generation targeted agents” Associate Professor of Ophthalmology Ocular Oncology and Vitreoretinal Surgery Director, Ocular Oncology Service Director, Vitreoretinal Surgery Fellowship Byers Eye Institute at Stanford University
31